In this MOA animation, we worked with Pfizer to share their vaccine development against Serogroup B Meningococcal Disease, or MenB. This lethal disease, caused by bacterial meningitis, primarily affects adolescents and young adults.
Over 97% of MenB strains have been found to express factor H binding protein, or fHBP. fHBP can be categorized into two immunologically distinct subfamilies: A and B. Trumenba is the first and only FDA-approved MenB vaccine that targets both subfamilies of fHBP.
This vaccine induces the production of antibodies that block the binding of fHBP, and therefore utilizes normal immune response mechanisms including complement-mediated bacterial lysis and phagocytic uptake to eradicate the bacteria.